

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (previously presented): A method of treating a human with psoriasis, comprising systemically administering to said human an amount of an EGFR/HER1 antibody effective to treat psoriasis.

2. (canceled)

3. (previously presented): A method according to claim 1 wherein the antibody is a monoclonal antibody specific for EGFR/HER1 or a fragment that comprises the hypervariable region thereof.

4. (original): A method according to claim 3 wherein the monoclonal antibody is chimerized or humanized.

5. (original): A method according to claim 3 wherein the monoclonal antibody inhibits EGFR/HER1 phosphorylation.

6-45. (canceled)

46. (previously presented): A method according to claim 1 wherein the antibody is administered intravenously.

47. (previously presented): A method according to claim 1 wherein the antibody comprises the following CDRs having the following amino acid sequences:

CDR1, SEQ ID 2;

CDR2, SEQ ID 4;

CDR3, SEQ ID 6;

CDR4, SEQ ID 8;

CDR5, SEQ ID 10;

CDR6, SEQ ID 12.

48. (currently amended): A method according to claim 47 wherein the antibody is 225 or ~~€225~~ chimeric 225.